Pharma Commercial Mock
← All views
Competitive intelligence

CI feed

Conference abstracts + payer decisions interleaved chronologically — the CI team aims to publish a structured briefing within 48 hours of any high-relevance event landing here.

2 items in window · 0 high-relevance

type:allabstractspayer decisionsrelevance:allhighmediumlow
  1. Congresslowembargo lifts in 1d
    Jun 1, 2026, 9:45 PM
    KEYNOTE-849: Keytruda (pembrolizumab) 2L in SCLC
    Median OS 10.6 months. HR 0.89 (95% CI 0.77–0.99). No new safety signals identified.
    Keytruda () · MerckSCLCKEYNOTE-849 · NCT63930156Oral Abstract Session
    OS
    10.6 months
    HR 0.89 (0.77-0.99)
    PFS
    4.3 months
    HR 0.87 (0.74-0.99)
    ORR
    61.3 percent
  2. Congresslowembargo lifts in 4d
    Jun 4, 2026, 5:45 PM
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-650
    Median OS 37.5 months. HR 0.87 (95% CI 0.76–0.98). Grade ≥3 AEs consistent with prior reports.
    Lynparza () · AstraZenecaprostateOlympiA-650 · NCT23801137Poster Discussion Session
    OS
    37.5 months
    HR 0.87 (0.76-0.98)
    PFS
    20.3 months
    HR 0.89 (0.75-0.99)
    ORR
    46.8 percent